TRANSLATION INHIBITORS OF HEPATITIS C VIRUS
丙型肝炎病毒的翻译抑制剂
基本信息
- 批准号:2864834
- 负责人:
- 金额:$ 19.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1999
- 资助国家:美国
- 起止时间:1999-09-30 至 2000-09-29
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
The long term objective of this proposal is to develop novel antiviral drugs effective against hepatitis C virus (HCV). HCV infection in humans leads to progressive destruction of the liver resulting in cirrhosis and heightened risk of hepatocellular carcinoma. Antiviral drugs (such as interferon) have had limited success in controlling HCV-induced liver disease. Two novel molecules have been discovered both of which block HCV protein synthesis without adversely affecting the host cell. This proposal will examine direct and liposome-mediated delivery of these molecules individually and in combination to the liver of experimental animals. In addition, distribution, stability and clearance of these molecules in liver and various other organs of mice will be determined. If successful, the efficacy of these molecules in blocking HCV infection can be studied in chimpanzees. It is hoped that the experiments proposed here will lead to development of novel antiviral drugs effective against HCV infection in humans. PROPOSED COMMERCIAL APPLICATION The experiments proposed here should yield important information leading to development of novel drugs effective against HCV infection in humans.
本研究的长期目标是开发有效对抗丙型肝炎病毒(HCV)的新型抗病毒药物。人类丙型肝炎病毒感染导致肝脏的进行性破坏,导致肝硬化和肝细胞癌的风险增加。抗病毒药物(如干扰素)在控制丙型肝炎引起的肝脏疾病方面取得了有限的成功。已经发现了两种新的分子,它们都能阻断HCV蛋白的合成,而不会对宿主细胞产生不利影响。本提案将研究这些分子单独或联合到实验动物肝脏的直接和脂质体介导的递送。此外,还将确定这些分子在小鼠肝脏和其他各种器官中的分布、稳定性和清除情况。如果成功,这些分子阻断丙型肝炎病毒感染的功效可以在黑猩猩身上进行研究。希望本文提出的实验将导致开发新的抗病毒药物有效地对抗人类丙型肝炎病毒感染。本文提出的实验将产生重要的信息,从而开发出有效对抗人类丙型肝炎病毒感染的新药。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ASIM DASGUPTA其他文献
ASIM DASGUPTA的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ASIM DASGUPTA', 18)}}的其他基金
The role of hepatitis C virus 5' untranslated region in virus morphogenesis
丙型肝炎病毒5非翻译区在病毒形态发生中的作用
- 批准号:
7897569 - 财政年份:2010
- 资助金额:
$ 19.44万 - 项目类别:
The role of hepatitis C virus 5' untranslated region in virus morphogenesis
丙型肝炎病毒5非翻译区在病毒形态发生中的作用
- 批准号:
8066747 - 财政年份:2010
- 资助金额:
$ 19.44万 - 项目类别:
Towards Developing type 1a HCV cell culture model
致力于开发 1a 型 HCV 细胞培养模型
- 批准号:
7454283 - 财政年份:2007
- 资助金额:
$ 19.44万 - 项目类别:
Towards Developing type 1a HCV cell culture model
致力于开发 1a 型 HCV 细胞培养模型
- 批准号:
7178904 - 财政年份:2007
- 资助金额:
$ 19.44万 - 项目类别:
TRANSLATION-INHIBITION OF HEPATITIS C AND POLIO VIRUSES
丙型肝炎和脊髓灰质炎病毒的翻译抑制
- 批准号:
6630523 - 财政年份:1999
- 资助金额:
$ 19.44万 - 项目类别:
TRANSLATION-INHIBITION OF HEPATITIS C AND POLIO VIRUSES
丙型肝炎和脊髓灰质炎病毒的翻译抑制
- 批准号:
6534167 - 财政年份:1999
- 资助金额:
$ 19.44万 - 项目类别:
TRANSLATION-INHIBITION OF HEPATITIS C AND POLIO VIRUSES
丙型肝炎和脊髓灰质炎病毒的翻译抑制
- 批准号:
6374202 - 财政年份:1999
- 资助金额:
$ 19.44万 - 项目类别:
TRANSLATION-INHIBITION OF HEPATITIS C AND POLIO VIRUSES
丙型肝炎和脊髓灰质炎病毒的翻译抑制
- 批准号:
6170392 - 财政年份:1999
- 资助金额:
$ 19.44万 - 项目类别:
TRANSLATION-INHIBITION OF HEPATITIS C AND POLIO VIRUSES
丙型肝炎和脊髓灰质炎病毒的翻译抑制
- 批准号:
2887979 - 财政年份:1999
- 资助金额:
$ 19.44万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 19.44万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 19.44万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 19.44万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 19.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 19.44万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 19.44万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 19.44万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 19.44万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 19.44万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 19.44万 - 项目类别: